Dinesh Keerty

Dinesh Keerty

Auto-generated profile, based on publicly available information

Dinesh Keerty

Internal Medicine, Moffitt Cancer Center , Tampa, Florida, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 April 2014 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
JCJuan Cata
Juan Cata
VKVisesh Keerty
Visesh Keerty
DKDinesh Keerty
Dinesh Keerty
LFLei Feng
Lei Feng
PNPeter H. Norman
Peter H. Norman
MEMitchel Engle
Mitchel Engle
Preclinical studies have demonstrated that opioid receptor agonists increase the rate of non‐small cell lung cancer (NSCLC) growth and metastasis. Following institutional review board approval, we retrieved data on 901 patients who underwent surgery for NSCLC at MD Anderson Cancer Center. Comprehensive demographics, intraoperative data, and recurrence‐free survival (RFS) and overall survival (OS) at 3 and 5 years were obtained. Cox proportional analyses were conducted to assess the association between intraoperative opioid exposure and RFS and OS. The median intraoperative fentanyl equivalents dosage was 10.15 μg/kg. The multivariate analysis by stage indicated that a trend toward significance for opioid consumption as a risk factor in stage I patients (P = 0.053). No effect was found on RFS for stage II or III patients. Alternatively, opioid consumption was a risk factor for OS for stage I patients (P = 0.036), whereas no effect was noted for stage II or III patients. Intraoperative opioid use is associated with decreased OS in stage I but not stage II–III NSCLC patients. Until randomized controlled studies explore this association further, opioids should continue to be a key component of balanced anesthesia.

1 March 2014 in Journal of Clinical Anesthesia
Verified
Journal Article
Closed access
JCJuan Cata
Juan Cata
JVJohn Villarreal
John Villarreal
DKDinesh Keerty
Dinesh Keerty
DTDilip R. Thakar
Dilip R. Thakar
DLDiane D. Liu
Diane D. Liu
VGVijaya Gottumukkala
Vijaya Gottumukkala

1 February 2014 in Journal of Clinical Anesthesia
Verified
Journal Article
Closed access
JCJuan Cata
Juan Cata
VGVijaya Gottumukkala
Vijaya Gottumukkala
DTDilip Thakar
Dilip Thakar
DKDinesh Keerty
Dinesh Keerty
RGRodolfo Gebhardt
Rodolfo Gebhardt
DLDiane D. Liu
Diane D. Liu

24 September 2020 in Cureus
Verified
Journal Article
Open access
PDF file
DKDinesh Keerty
Dinesh Keerty
MDManoj Das
Manoj Das
JJJulie Hallanger Johnson
Julie Hallanger Johnson
EHElizabeth Haynes
Elizabeth Haynes
Immune checkpoint inhibitors (ICPIs), such as anti-programmed death receptor 1 (PD-I) and anti-cytotoxic T-Iymphocyte-associated antigen 4 (CTLA-4), are being utilized in the treatment of many malignancies. Just like their benefits in increasing recurrence-free survival, they also have shown numerous side effects affecting various organ systems. The endocrine adverse events can range from diabetes, hypothyroidism to diabetic ketoacidosis, and adrenal crisis. We would like to report a case of diabetic ketoacidosis (DKA) secondary to combination ipilimumab and nivolumab therapy after two doses. A 49-year-old female presented to the emergency department with nausea and vomiting. Her labs revealed blood glucose of 384 mg/dL, positive ketones, glucose in the urine, and an arterial pH of 7.2. She was treated as per our diabetic ketoacidosis protocol and ultimately discharged on insulin therapy. Clinicians should he vigilant about new hyperglycemic episodes in their patients who are on immunotherapy. Timely detection and management lead to better outcomes. Insulin is the standard treatment of choice in the treatment of immunotherapy mediated type I diabetes mellitus.

13 May 2020 in Cureus
Verified
Journal Article
Open access
PDF file
DKDinesh Keerty
Dinesh Keerty
LGLaura Graham
Laura Graham
EHElizabeth Haynes
Elizabeth Haynes
THTimothy N. Hembree
Timothy N. Hembree
Urothelial malignancies are commonly treated with platinum-based therapies. Newer trials have tested antimitotic therapies such as enfortumab vedotin as viable treatment therapy for refractory malignany. Enfortumab vedotin targets nectin-4, a member of a family of calcium-dependent, immunoglobulin-like adhesion molecules found in adherens junctions and expressed in various epithelial malignancies, including bladder, breast, lung, ovarian, head/neck, and esophageal cancers. We present a case of a patient with symmetrical drug-related intertriginous and flexural exanthema secondary to enfortumab. He was successfully treated with topical corticosteroids. Cutaneous toxicity appears to be a common adverse reaction in this growing class of antibody-drug conjugates.

6 August 2020 in Cureus
Verified
Journal Article
Open access
PDF file
DKDinesh Keerty
Dinesh Keerty
VKViktoriya Koverzhenko
Viktoriya Koverzhenko
DBDalila Belinc
Dalila Belinc
KLKatie LaPorta
Katie LaPorta
EHElizabeth Haynes
Elizabeth Haynes
The treatment of melanoma has advanced over time with the latest modalities being immune checkpoint blockade by programmed death receptor 1 and cytotoxic T-lymphocyte-associated antigen 4 inhibitors. Programmed death receptor 1 inhibitors have been noted to cause multi-system adverse reactions. The dermatological adverse events can range from pruritus to severe toxic epidermal necrolysis. We report a fatal case of toxic epidermal necrolysis secondary to nivolumab therapy. Checkpoint inhibitors are becoming the standard treatment option in many malignancies. Their safety profile is still evolving as more cases are being reported. Many individuals who are immunocompromised or undergoing concomitant treatment with combination therapy could develop significant overlapping toxicities. Physicians must be vigilant for dermatological complications that lead to opportunistic infections and sepsis.